docetaxel anhydrous has been researched along with Phlebitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borley, A; Dolan, G; Hanna, L; Roberts, R; Williams, EM | 1 |
| Leonard, GD; Zujewski, JA | 1 |
2 other study(ies) available for docetaxel anhydrous and Phlebitis
| Article | Year |
|---|---|
Epirubicin chemotherapy in women with breast cancer: Alternating arms for intravenous administration to reduce chemical phlebitis.
Topics: Administration, Intravenous; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Injection Site Reaction; Middle Aged; Phlebitis; Prospective Studies | 2019 |
Docetaxel-related skin, nail, and vascular toxicity.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Forearm; Humans; Infusions, Intravenous; Middle Aged; Nail Diseases; Paclitaxel; Phlebitis; Skin Diseases; Taxoids; Toes | 2003 |